Toripalimab - Shanghai Junshi Biosciences
Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi Biosciences; CHS-007; JS 001; JS-001sc; LOQTORZI; SO-001; TAB-001; Terepril monoclonal antibody; toripalimab-tpzi; Treipril monoclonal antibody; Treprizumab; Treprizumab - Shanghai Junshi Biosciences; Tripleitriumab; Triprizumab; TUOYI; TuoyiLatest Information Update: 25 Jul 2024
At a glance
- Originator Elpiscience Biopharmaceuticals; Shanghai Junshi Biosciences
- Developer Ascentage Pharma; Coherus BioSciences; Fudan University; GenFleet Therapeutics; HUTCHMED; I-MAB Biopharma; Peking Union Medical College Hospital; Peking University; RemeGen; Shanghai Junshi Biosciences; Sun Yat-Sen University; Suzhou Yasheng Pharmaceutical; Xiangya Hospital of Central South University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer; Urogenital cancer
- Registered Renal cancer; Small cell lung cancer; Triple negative breast cancer
- Preregistration Liver cancer
- Phase III Gastric cancer; Hodgkin's disease; Neuroendocrine tumours
- Phase II Biliary cancer; Bladder cancer; Breast cancer; Cancer; Colorectal cancer; Solid tumours; Thyroid cancer
- Phase I/II Head and neck cancer; Liposarcoma; Lung cancer
- No development reported Alveolar soft part sarcoma; Lymphoma
Most Recent Events
- 18 Jul 2024 Preregistration for Liver cancer (Combination therapy, Inoperable/Unresectable, First-line therapy, Late-stage disease, Metastatic disease) in China (IV) before July 2024
- 18 Jul 2024 National Medical Products Administration (NMPA), China accepts sBLA for Toripalimab for Liver cancer (Combination therapy, First-line therapy) in China (IV) for review
- 11 Jul 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Recurrent, Metastatic disease) in China (SC) (NCT06505837)